Progenics Pharma (PGNX) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results
March 16, 2015 8:02 AM EDTTARRYTOWN, N.Y., March 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year-end 2014.
"We have reported significant progress in recent months, and begin 2015 with a pivotal trial underway for Azedra, two Phase 3-ready prostate cancer programs, and a strong balance sheet to support our high-value pipeline," stated Mark Baker, CEO of Progenics. "The data emerging from our PSMA ADC and 1404 programs are quite impressive, demonstrating the potential of these product candidates to change the way prostate cancer is diagnosed, monitored and treated.... More
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results
March 16, 2015 8:00 AM EDTTARRYTOWN, N.Y., March 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year-end 2014.
"We have reported significant progress in recent months, and begin 2015 with a pivotal trial underway for Azedra, two Phase 3-ready prostate cancer programs, and a strong balance sheet to support our high-value pipeline," stated Mark Baker, CEO of Progenics. "The data emerging from our PSMA ADC and 1404 programs are quite impressive, demonstrating the potential of these product candidates to change the way prostate cancer is diagnosed, monitored and treated.... More
